Overexpression of micro ribonucleic acid-591 inhibits cell proliferation and invasion of malignant pleural mesothelioma cells.

Abstract:

BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive cancer refractory to current therapies. Reduced expression of micro ribonucleic acid (miR)-591 in a range of cancer types has suggested it is a potent tumor suppressor, and overexpression has been shown to inhibit tumor cell growth. The role of miR-591 in MPM is largely unknown. METHODS:miR-591 was over-expressed in vitro using micro RNA mimics in three MPM cell lines (H513, H2052, H2373), and effects on tumor cell growth, proliferation, invasion, and target gene expression were assessed. RESULTS:miR-591 mimic was introduced into MPM cell lines to overexpress this microRNA. The cellular growth, proliferation, and invasive capability was significantly inhibited after overexpression of miR-591. Growth inhibition caused by miR-591 correlated with upregulation of p21 and Bax. Reduced invasive capability correlated with downregulation of matrix metalloproteinase-2 and transforming growth factor-β1. CONCLUSION:miR-591 is a potent tumor suppressor in MPM. Overexpression of miR-591 may represent a novel therapeutic approach for MPM.

journal_name

Thorac Cancer

journal_title

Thoracic cancer

authors

Cheng S,Xu Y,Shi Z,Lin Y,Hoang CD,Zhang X

doi

10.1111/1759-7714.12336

subject

Has Abstract

pub_date

2016-04-26 00:00:00

pages

340-7

issue

3

eissn

1759-7706

issn

1759-7714

pii

TCA12336

journal_volume

7

pub_type

杂志文章
  • Review of aerobic glycolysis and its key enzymes - new targets for lung cancer therapy.

    abstract::Most tumor cells show different metabolic pathways than normal cells. Even under the conditions of sufficient oxygen, they produce energy by a high rate of glycolysis followed by lactic acid fermentation in the cytosol, which is known as aerobic glycolysis or the Warburg effect. Lung cancer is a malignant tumor with o...

    journal_title:Thoracic cancer

    pub_type: 杂志文章,评审

    doi:10.1111/1759-7714.12148

    authors: Li XB,Gu JD,Zhou QH

    更新日期:2015-01-01 00:00:00

  • Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis.

    abstract:BACKGROUND:S-1 monotherapy is effective and feasible for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, it is not clear whether its effectiveness and tolerability in elderly patients are equivalent to those in younger patients. Hence, this study aimed to evaluate the efficacy and...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13622

    authors: Imai H,Minemura H,Kishikawa T,Yamada Y,Suzuki K,Umeda Y,Wasamoto S,Kasahara N,Ishihara S,Yamaguchi O,Naruse I,Uchino J,Mori K,Kanazawa K,Shibata Y,Kasai T,Kaburagi T,Kaira K,Minato K

    更新日期:2020-10-01 00:00:00

  • Circulating tumor cells in the pulmonary vein increase significantly after lobectomy: A prospective observational study.

    abstract:BACKGROUND:It has been reported that there are more circulating tumor cells (CTCs) in the pulmonary vein (PV) than in the peripheral blood; however, it is unclear whether the CTC count changes in the PV after resection of a lung lobe. METHODS:Thirty-three lung cancer patients were recruited for the study, including 17...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12925

    authors: Duan X,Zhu Y,Cui Y,Yang Z,Zhou S,Han Y,Yu D,Xiao N,Cao X,Li Y,Liu S,Wang Z,Zhang W,Feng L,Zhang K,Shou J,Liu Z,Xu S

    更新日期:2019-02-01 00:00:00

  • Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.

    abstract::Pulmonary pleomorphic carcinoma (PPC) is a very rare type of primary lung cancer with an aggressive clinical course. Few reports have documented therapeutic options for PPC with EGFR mutations. Herein, we report a case of PPC with EGFR mutation treated with EGFR-tyrosine kinase inhibitors (TKIs). A 65-year-old Japanes...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12646

    authors: Masuda K,Tokito T,Azuma K,Yanagida E,Nakamura M,Naito Y,Matsuo N,Ishii H,Yamada K,Akiba J,Hoshino T

    更新日期:2018-06-01 00:00:00

  • Lung adenocarcinoma with anomalous bronchi and pulmonary veins preoperatively identified by computed tomography.

    abstract::A 69-year-old woman visited our hospital complaining of right chest pain. Chest computed tomography showed a 55 × 45 mm tumor in the right upper lobe. Bronchoscopy revealed displaced anomalous B 1 and B 2+3 arising from the right main bronchus, and the patient was diagnosed with lung adenocarcinoma by transbronchial l...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12362

    authors: Tajima K,Uchida N,Sasamoto H,Okada T,Kohri T,Mogi A,Kuwano H

    更新日期:2016-09-01 00:00:00

  • Lung adenocarcinoma initially presenting as Trousseau's syndrome treated successfully with pembrolizumab: A case report.

    abstract::A 60-year-old woman was urgently admitted to our hospital because of vertigo and left hemiplegia. Laboratory examination showed thrombocytopenia, high levels of D-dimer and carcinoembryonic antigen. Brain magnetic resonance imaging (MRI) revealed multiple bilateral cerebral infarctions. Chest computed tomography (CT) ...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13794

    authors: Nakano Y,Koide N,Koyama Y,Nitta K,Koizumi T

    更新日期:2020-12-21 00:00:00

  • Short-term local control after VATS segmentectomy and lobectomy for solid NSCLC of less than 2 cm.

    abstract:INTRODUCTION:VATS pulmonary segmentectomy is increasingly proposed as a parenchyma-sparing resection for tumors smaller than 2 cm in diameter. The aim of this study was to compare short-term oncological results and local control in solid non-small cell lung cancers (NSCLCs) <2 cm surgically treated by intentional VATS ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13766

    authors: Darras M,Ojanguren A,Forster C,Zellweger M,Perentes JY,Krueger T,Gonzalez M

    更新日期:2020-12-03 00:00:00

  • Cloning short DNA into plasmids by one-step PCR.

    abstract:BACKGROUND:Plasmid construction of small fragments of interest (such as insertion of small fragment marker genes, expression of shRNA, siRNA, etc) is the basis of many biomolecular experiments. Here, we describe a method to clone short DNA into vectors by polymerase chain reaction (PCR), named one-step PCR cloning. Our...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13660

    authors: Tao CC,Yang Y,Li F,Qiao L,Wu Y,Sun XD,Zhang YY,Li CL

    更新日期:2020-11-01 00:00:00

  • ALK-rearrangement in non-small-cell lung cancer (NSCLC).

    abstract::The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large-cell lymphoma. Since then, ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章,评审

    doi:10.1111/1759-7714.12613

    authors: Du X,Shao Y,Qin HF,Tai YH,Gao HJ

    更新日期:2018-04-01 00:00:00

  • The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute.

    abstract:BACKGROUND:The efficacy of amrubicin for relapsed small-cell lung cancer (SCLC) has been reported in previous studies. Few reports, however, describe the efficacy and survival benefit of third-line amrubicin chemotherapy in patients with extensive disease (ED)-SCLC. METHODS:We retrospectively analyzed the clinical rec...

    journal_title:Thoracic cancer

    pub_type: 临床试验,杂志文章

    doi:10.1111/1759-7714.13150

    authors: Sonehara K,Tateishi K,Fukushima T,Komatsu M,Yamamoto H,Koizumi T,Hanaoka M

    更新日期:2019-09-01 00:00:00

  • CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.

    abstract::ROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated re...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12617

    authors: Zhu YC,Zhou YF,Wang WX,Xu CW,Zhuang W,Du KQ,Chen G

    更新日期:2018-05-01 00:00:00

  • P16INK4a gene promoter methylation as a biomarker for the diagnosis of non-small cell lung cancer: An updated meta-analysis.

    abstract:BACKGROUND:This meta-analysis was conducted to investigate the diagnostic performance of P16INK4a gene promoter methylation as a biomarker of non-small cell lung cancer (NSCLC). METHODS:Two reviewers independently searched the Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, and Chine...

    journal_title:Thoracic cancer

    pub_type: 杂志文章,meta分析

    doi:10.1111/1759-7714.12783

    authors: Tuo L,Sha S,Huayu Z,Du K

    更新日期:2018-08-01 00:00:00

  • Three-dimensional (3D)-printed titanium sternum replacement: A case report.

    abstract::After sternal tumor resection, reconstruction of chest wall defects is still a challenging part of thoracic surgery. Three-dimensional (3D)-printed titanium alloy prosthesis implants provide an effective solution. The bionic bone trabecular micropore structure, which is beneficial to the human body, increases stabilit...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13655

    authors: Wang W,Liang Z,Yang S,Feng Q,Nie X,Su G,Yuan W,Han Y

    更新日期:2020-11-01 00:00:00

  • miR-874 directly targets AQP3 to inhibit cell proliferation, mobility and EMT in non-small cell lung cancer.

    abstract:BACKGROUND:Non-small cell lung cancer (NSCLC) is a major type of lung cancer with high morbidity and high mortality. miR-874 has been determined to play a role in tumor suppression in several cancers. The purpose of our study was to detect the biological mechanisms of miR-874 and AQP3 in NSCLC. METHODS:CCK-8 and Trans...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13428

    authors: Wang S,Wu Y,Yang S,Liu X,Lu Y,Liu F,Li G,Tian G

    更新日期:2020-06-01 00:00:00

  • Capn4 promotes esophageal squamous cell carcinoma metastasis by regulating ZEB1 through the Wnt/β-catenin signaling pathway.

    abstract:BACKGROUND:Capn4 and ZEB1 play important roles in the metastasis of several types of cancer. However, the roles and relationship of Capn4 and ZEB1 in esophageal squamous cell carcinoma (ESCC) remain unclear. METHODS:ESCC tumor tissues and corresponding normal esophageal epithelial tissues were obtained from 86 patient...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12893

    authors: Zhao YL,Li JB,Li YJ,Li SJ,Zhou SH,Xia H

    更新日期:2019-01-01 00:00:00

  • Serum exosomal miR-1269a serves as a diagnostic marker and plays an oncogenic role in non-small cell lung cancer.

    abstract:BACKGROUND:Early diagnosis improves the prognosis for non-small cell lung cancer (NSCLC); therefore, there is a pressing need for effective diagnostic methods for NSCLC. Increasing evidence indicates that serum exosomal micro RNAs (miRNAs) represent promising diagnostic and prognostic markers for multiple cancers. Here...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13644

    authors: Wang X,Jiang X,Li J,Wang J,Binang H,Shi S,Duan W,Zhao Y,Zhang Y

    更新日期:2020-12-01 00:00:00

  • Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.

    abstract:BACKGROUND:Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life-threatening adverse event. The purpose of this study was to evaluate whether the development of immune-related adverse events (irAEs), especially ILD, was associated with treatment efficacy and to research th...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13364

    authors: Sugano T,Seike M,Saito Y,Kashiwada T,Terasaki Y,Takano N,Hisakane K,Takahashi S,Tanaka T,Takeuchi S,Miyanaga A,Minegishi Y,Noro R,Kubota K,Gemma A

    更新日期:2020-04-01 00:00:00

  • Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors.

    abstract:BACKGROUND:Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (NSCLC), and targeting the PD-1 or PD-L1 pathway is a promising therapeutic option. Although PD-1/PD-L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because o...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12877

    authors: Kang DH,Chung C,Kim JO,Jung SS,Park HS,Park DI,Jung SY,Park M,Lee JE

    更新日期:2018-11-01 00:00:00

  • Lung cancer in patients with and without rheumatoid arthritis: A propensity score-matched survival analysis cohort study.

    abstract:BACKGROUND:Connective tissue disease increases the risk of lung cancer, but whether rheumatoid arthritis (RA) has an effect on the overall survival (OS) rate in this population has not been well studied. METHODS:Patients diagnosed with lung cancer between January 2015 and December 2017 were enrolled in this retrospect...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13388

    authors: Zhang L,Zhao Q,Yuan F,Liu M

    更新日期:2020-06-01 00:00:00

  • The 12th National Lung Cancer Academic Conference in China.

    abstract:BACKGROUND:  The 12th National Lung Cancer Academic Conference was held in Wu Han, China in 2011. METHODS:  The content of the conference involved recent research achievements and progress in the field of lung cancer, including the epidemiology of lung cancer and molecules, new methods and technology for early-screeni...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/j.1759-7714.2012.00125.x

    authors: Liu Y,Chen G,Qiu X,Chen J,Zhou Q

    更新日期:2012-08-01 00:00:00

  • Association of Chlamydia pneumoniae immunoglobulin G antibodies with the risk of lung cancer among non-smoking women in Liaoning, China.

    abstract::The role of Chlamydia pneumoniae in the cause of lung cancer is controversial. In this study, we investigated the association between C. pneumoniae immunoglobulin (Ig) G antibodies and risk of lung cancer among non-smoking women. C. pneumoniae IgG antibody levels were compared between 192 adult Chinese women who met t...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/j.1759-7714.2010.00021.x

    authors: Liu Z,Su M,Yu SC,Yin ZH,Zhou BS

    更新日期:2010-09-01 00:00:00

  • Surgical outcomes of 215 patients with thymic epithelial tumors: A single-center experience.

    abstract:OBJECTIVES:To evaluate the oncological prognosis and neurological outcomes for patients with thymic epithelial tumors (TETs) after thymectomy. METHODS:Consecutive patients with TETs who underwent thymectomy at Beijing Hospital from January 2011 to December 2018 were retrospectively enrolled into the study. Clinical, p...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13464

    authors: Tian W,Sun Y,Wu Q,Jiao P,Ma C,Yu H,Huang C,Tong H

    更新日期:2020-07-01 00:00:00

  • Management of immune checkpoint inhibitor-related dermatologic adverse events.

    abstract::Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune-related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy-related adverse events. The most common symptoms are maculopapular rash and pru...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13275

    authors: Si X,He C,Zhang L,Liu X,Li Y,Wang H,Guo X,Zhou J,Duan L,Wang M,Zhang L

    更新日期:2020-02-01 00:00:00

  • A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer.

    abstract:BACKGROUND:To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non-small-cell lung cancer (NSCLC). METHODS:Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two gro...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13238

    authors: Nie K,Zhang Z,You Y,Zhuang X,Zhang C,Ji Y

    更新日期:2020-01-01 00:00:00

  • Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective study.

    abstract:BACKGROUND:  The optimal strategy was not established for patients who initially responded to gefitinib although re-administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been proven to be an option. Gefitinib and erlotinib were compared as salvage treatment after gefitinib fail...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/j.1759-7714.2012.00152.x

    authors: Yu S,Wang Y,Li J,Hao X,Wang B,Wang Z,Zhang X,Shi Y

    更新日期:2013-05-01 00:00:00

  • Self-reported depression among patients with non-small cell lung cancer.

    abstract:BACKGROUND:Lung cancer is a disease with a poor prognosis and psychological impact. Lung cancer causes both physical and psychological burdens on patients, and financial burdens on families and society. The aim of this study was to examine the relationship between depression and influencing factors in non-small-cell lu...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12179

    authors: Shi Y,Gu F,Hou LL,Hu YQ

    更新日期:2015-05-01 00:00:00

  • p100 functions as a metastasis activator and is targeted by tumor suppressing microRNA-320a in lung cancer.

    abstract:BACKGROUND:Lung cancer is among the most frequently diagnosed types of cancer worldwide, with high morbidity and mortality. Metastasis accounts for the deadliest and most poorly understood feature of lung cancer. Herein, we demonstrate that SND1 (also known as p100) acts as a candidate metastasis activator and is targe...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12564

    authors: Xing A,Pan L,Gao J

    更新日期:2018-01-01 00:00:00

  • Invasive thymoma with intravascular growth into the great veins and right atrium: A case report.

    abstract::Here, we present a case of invasive thymoma with intraluminal growth into the left and right brachiocephalic veins, superior vena cava and the right atrium. Resection of the mass, double partial upper lobe lobectomy and superior vena cava, and left and right brachiocephalic vein replacement were performed. Pathologica...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13242

    authors: Shen W,Cao Y,Wang X,Zhang P,Zhou Q

    更新日期:2020-05-01 00:00:00

  • Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.

    abstract:BACKGROUND:This study evaluated the efficacy and safety of retreatment with anti-programmed death 1 (anti-PD-1) antibodies in patients with advanced non-small cell lung cancer (NSCLC) after prior treatment with anti-programmed death-ligand 1 (anti-PD-L1) antibodies. METHODS:Data (N = 15) on patients' characteristics, ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13241

    authors: Fujita K,Yamamoto Y,Kanai O,Okamura M,Hashimoto M,Nakatani K,Sawai S,Mio T

    更新日期:2020-01-01 00:00:00

  • Immune checkpoint inhibitors-induced eosinophilic pneumonia: A case report.

    abstract::A 78-year-old male with renal cell carcinoma was treated with combined immunotherapy of nivolumab and ipilimumab. After four courses of the treatment, a chest computed tomography (CT) revealed newly formed ground-glass opacities (GGOs) in both the lower lung lobes; drug-induced pneumonia was speculated. Eosinophil cou...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13848

    authors: Hara K,Yamasaki K,Tahara M,Kimuro R,Yamaguchi Y,Suzuki Y,Kawabata H,Kawanami T,Fujimoto N,Yatera K

    更新日期:2021-01-21 00:00:00